Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Uranium Energy Corp (UEC) Price & Performance

Heron Therapeutics IncTrade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Uranium Energy Corp — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Uranium Energy Corp trades at $11.65 (market cap $5.63B). The key difference: Uranium Energy Corp is far larger — about 88.8× Heron Therapeutics Inc's market cap, and Uranium Energy Corp is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXUEC
Market Cap
$63.41M$5.63B
Sector
HealthEnergy
52-Week High
$1.49$20.14
52-Week Low
$0.32$9.04
Enterprise Value
$161.31M$5.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Uranium Energy Corp

UEC trades at $11.26, up 4.65% in the last 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces profitability challenges with a negative net income margin of -513.24%. Recent news highlights optimism around nuclear energy growth, but financial performance remains under pressure.

Outlook is mixed: strong analyst buy ratings (87.5%) and sector tailwinds support potential, but persistent losses, high P/S ratio of 265.97, and execution risks pose significant challenges. Investors should weigh the speculative growth narrative against fundamental weaknesses and cash flow concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC